Single domain antibodies: A new concept for epidermal growth factor receptor and EGFRvIII targeting

DNA and Cell Biology

Volumn 31, Issue 6, 2012, Pages 1015-1026

  Omidfar, Kobra ^a   Shirvani, Zaynab ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR VIII MONOCLONAL ANTIBODY; GEMTUZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; NIMOTUZUMAB; OFATUMUMAB; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; VIRUS TYPING;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

CAMELIDAE;

EID: 84864035249     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1529     Document Type: Article

References (121)

1. Adams, G.P., Schier, R., McCall, A.M., Simmons, H.H., Horak, E.M., Alpaugh, R.K., Marks, J.D., and Weiner, L.M. (2001). High affinity restricts the localization and tumor penetration of single- chain fv antibody molecules. Cancer Res 61, 4750-4755.
2. Aldape, K.D., Ballman, K., Furth, A., Buckner, J.C., Giannini, C., Burger, P.C., Scheithauer, B.W., Jenkins, R.B., and James, C.D. (2004). Imunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63, 700-707.
3. Alroy, I., and Yarden, Y. (1997). The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand/receptor interactions. FEBS Lett 410, 83-86.
4. Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., and Muyldermans, S. (1997). Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414, 521-526.
5. Baselga, J. (2002). Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7, 2-8.
6. Beers, R., Chowdhury, P., Bigner, D., and Pastan, I. (2000). Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 6, 2835-2843.
7. Behring, E., and Kitasato, S. (1890). Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitatbeithieren. Deutsche medizinscheWochenschrift 16:1113-1114. In Milestones in Microbiology: 1556 to 1940, translated and edited by Thomas D. Brock (ASM Press, American Society for Microbiology, 1998), pp. 138-140.
8. Bell, A., Wang, Z.J., Arbabi-Ghahroudi, M., Chang, T.A., Trojahn, Y.D.U., Baardsnes, J., Jaramillo, M.L., Li, S., Baral, T., OConnor-McCourt, M., MacKenzie, R., and Zhang, J. (2010). Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett 289, 81.
9. Boland, W., and Bebb, G. (2009). Nimotuzumab: a novel anti- EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol 9, 1199-1206.
10. Boulianne, G.L., Hozumi, N., and Shulman, M.J. (1984). Production of functional chimeric mouse-human antibody. Nature 312, 643-646.
11. Burvenich, I., Schoonooghe, S., Cornelissen, B., Blanckaert, P., Coene, E., Cuvelier, C., Mertens, N., and Slegers, G. (2005). In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody14C5 in a non-small cell lung cancer and colon carcinoma model. Clin Cancer Res 11, 7288-7296.
12. Ciardiello, F., and Tortora, G. (2008). EGFR antagonists in cancer treatment. N Engl J Med 358, 1160-1174.
13. Citri, A., and Yarden, Y. (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7, 505-516.
14. Cohenuram, M., and Saif, M.W. (2007). Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18, 7-15.
15. Cortez-Retamozo,V., Backmann, N., Senter, P.D., Wernery, U., De Baetselier, P., Muyldermans, S., and Revets, H. (2004). Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64, 2853-2857.
16. Davies, J., and Riechmann, L. (1996). Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding. Immunotechnology 2, 169-179.
17. De Genst, E., Handelberg, F., Van Meirhaeghe, A., Vynck, S., Loris, R., Wyns, L., and Muyldermans, S. (2004). Chemical basis for the affinity maturation of a camel single domain antibody. J Biol Chem 279, 53593-53601.
18. Deffar, K., Shi, H., Li, L., Wang, X., and Zhu, X. (2009). Nanobodies- the new concept in antibody engineering. Afr J Biotechnol 8, 2645-2652.
19. Dienstmann, R., and Tabernero, J. (2010). Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investing Drugs 11, 1434-1441.
20. Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L.G., Muyldermans, S., Wyns, L., and Matagne, A. (2002). Single-domain antibody fragments with high conformational stability. Protein Sci 11, 500-515.
21. Feldkamp, M.M., Lala, P., Lau, N., Roncari, L., and Guha, A. (1999). Expression of activated epidermal factor receptors, Ras-guanosinetrihosphate, and mitogen activated protein kinase in human glioblastoma multiform specimens. Neurosurgery 45, 1442-1453.
22. Filpula, D. (2007). Antibody engineering and modification technologies. Biomol Eng 24, 201-215.
23. Gainkam, L.O., Huang, L., Caveliers, V., Keyaerts, M., Hernot, S., Vaneycken, I., Vanhove, C., Revets, H., De Baetselier, P., and Lahoutte, T. (2008). Comparison of the biodistribution and tumor targeting of Two 99mTc-labeled Anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 49, 788-795.
24. Garrett, T.P., McKern, N.M., Lou, M., Elleman, T.C., Adams, T.E., Lovrecz, G.O., Zhu, H.J., Walker, F., Frenkel, M.J., Hoyne, P.A., Jorissen, R.N., Nice, E.C., Burgess, A.W., and Ward, C.W. (2002). Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110, 763-773.
25. Ge, H., Gong, X., and Tang, C.K. (2002). Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 98, 357-361.
26. Goel, A., Colcher, D., Baranowska-Kortylewicz, J., Augustine, S., Booth, B.J., Pavlinkova, G., and Batra, S.K. (2000). Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res 60, 6964-6971.
27. Goldenberg, D.M., and Sharkey, R.M. (2007). Novel radiolabeled antibody conjugates. Oncogene 26, 3734-3744.
28. Graeven, U., Kremer, B., Sudhoff, T., Killing, B., Rojo, F., Weber, D., Tillner, J., Üna, C., and Schmiege, W. (2006). Phase I study of the humanized anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94, 1293-1299.
29. Greenberg, A.S., Avila, D., Hughes, M., Hughes, A., McKinney, E.C., and Flajnik, M.F. (1995). A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 374, 168-173.
30. Gullick, W.J. (1991). Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47, 87-98.
31. Gupta, P., Han, S.Y., Holgado-Madruga, M., Mitra, S.S., Li, G., Nitta, R.T., and Wong, A.J. (2010). Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol 10, 1-13.
32. Haley, J., Whittle, N., Bennet, P., Kinchington, D., Ullrich, A., and Waterfield, M. (1987). The human EGF receptor gene: Structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res 1, 375-396.
33. Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E.B., Bendahman, N., and Hammers, R. (1993). Naturally occurring antibodies devoid of light chains. Nature 363, 446-448.
34. Hensa, M., Vaidyanathana, G., Zhaoa, X.G., Bignerb, D.D., and Zalutskya, M.R. (2010). Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 37, 741-750.
35. Hills, D., Rowlinson-Busza, G., and Gullick, W.J. (1995). Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 63, 537-543.
36. Holliger, P., and Hudson, P.J. (2005). Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23, 1126-1136.
37. Hu, S., Shively, L., Raubitschek, A., Sherman, M., Williams, L.E., Wong, J.Y., Shively, J.E., and Wu, A.M. (1996). Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, highlevel targeting of xenografts. Cancer Res 56, 3055-3061.
38. Huang, L., Gainkam, L.O., Caveliers, V., Vanhove, C., Keyaerts, M., De Baetselier, P., Axel, B., Revets, H., and Tony, L. (2008) SPECT imaging with (99 m)Tc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 10, 167-175.
39. Humphrey, P.A., Wong, A.J., Vogelstein, B., Zalutsky, M.R., Fuller, G.N., Archer, G.E., Friedman, H.S., Kwatra, M.M., Bigner, S.H., and Bigner, D.D. (1990). Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci 87, 4207-4211.
40. Hynes, N.H., and Lane,H.A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5, 341-354.
41. Imai, K., and Takaoka, A. (2006). Comparing antibody and smallmolecule therapies for cancer. Nat Rev Cancer 6, 714-727.
42. Iqbal, U., Trojahn, U., Albaghdadi, H., Zhang, J., OConnor- McCourt, M., Stanimirovic, D., Tomanek, B., Sutherland, G., and Abulrob, A. (2010). Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. Br J Pharma1 60, 1016-1028.
43. Jain, M., Chauhan, S.C., Singh, A.P., Venkatraman, G., Colcher, D., and Batra, S.K. (2005). Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res 65, 7840-7846.
44. Jeroen, J., Bueren, L.V., Bleeker, W.K., Brannstrom, A., von Euler, A., Jansson, M., Peipp, M., Schneider-Merck, T., Valerius, T., van de Winkel, J.G., Paul, W., and Parren, H.I. (2008). The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci 105, 6109-6114.
45. Jespers, L., Schon, O., Famm, K., and Winter, G. (2004). Aggregation- resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 22, 1161-1165.
46. Jiang, H., Wang, H., Tan, Z., Hu, S., Wang, H., Shi, B., Yang, L., Li, P., Gu, J., Wang, H., and Li, Z. (2011). Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem 286, 5913-5920.
47. Johns, T.G., Adams, T.E., Cochran, J.R., Hall, N.E., Hoyne, P.A., Olsen, M.J., Kim, Y.S., Rothacker, J., Nice, E.C., Walker, F., Ritter, G., Jungbluth, A.A., Old, L.J., Ward, C.W., Burgess, A.W., Wittrup, K.D., and Scott, A.M. (2004). Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 279, 30375-30384.
48. Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S., and Winter, G. (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525.
49. Kamat, V., Donaldson, J.M., Kari, C., Quadros, M.R., Lelkes, P.I., Chaiken, I., Cocklin, S., Williams, J.C., Papazoglou, E., and Rodeck, U. (2008). Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 7, 726-733.
50. Kashanian, S., Rasaee, M.J., Paknejad, M., Omidfar, K., Pour Amir, M., and Rajabi, M. (2002). Preparation and characterization of monoclonal antibody against Digoxin. Hyrid Hybridomics 21, 375-379.
51. Kenanova, V., Olafsen, T., Williams, L.E., Ruel, N.H., Longmate, J., Yazaki, P.J., Shively, J.E., Colcher, D., Raubitschek, A.A., and Wu, A.M. (2007). Radioiodinated versus radiometal- labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res 67, 718-726.
52. Kuan, C.T., Reist, C.J., Foulon, C.F., Lorimer, I.A., Archer, G., Pegram, C.N., Pastan, I., Zalutsky, M.R., and Bigner, D.D. (1999). 125I-labeled anti-epidermal growth factor receptor-vIII single chain Fv exhibits specific and high-level targeting of gliomaxenografts. Clin Cancer Res 5, 1539-1549.
53. Kuan, C.T., Wikstrand, C.J., Archer, G., Beers, R., Pastan, I., Zalutskym, M.R., and Bigner, D.D. (2000). Increased binding affinity enhances targeting of gliomaxenografts by EGFRvIIIspecific scFv. Int J Cancer 88, 962-969.
54. Kuan, C.T., Wikstrand, C.J., and Bigner, D.D. (2001). EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8, 83-96.
55. Li, D., Ji, H., Zaghlul, S., McNamara, K., Liang, M.C., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L.R., Padera, R.F., Scott, A M., Jungbluth, A A., Cavenee, W.K., Old, L J., Demetri, G.D., and Wong K.K. (2007). Therapeutic anti- EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest 117, 346-352.
56. Li, S., Zheng, W., Kuolee, R., Hirama, T., Henry, M., Makvandi- Nejad, S., Chen T.F.W., and Zhang, J. (2009). Pentabodymediated antigen delivery induces antigen-specific mucosal immune response. Mol Immunol 46, 1718-1726.
57. Lo, H.W., Cao, X., Zhu, H., and Ali-Osman, F. (2010). COX-2 is a novel transcriptional target of the nuclear EGFRSTAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res 8, 232-245.
58. Lorimer, I.A.J. (2002). Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2, 91-102.
59. Luwor, R.B., Johns, T.G., Murone, C., Huang, H.J., Cavenee, W.K., Ritter, G., Old, L.J., Burgess, A.W., and Scott, A.M. (2001). Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61, 5355-5361.
60. Machiels, J.P., Subramanian, S., Ruzsa, A., Repassy, G., Lifirenko, I., Flygare, A., Sqrense, P., Nielsen, T., Lisby, S., and Clement, P.M. (2011). Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 12, 333-343.
61. Martinelli, E., Palma R.D., Orditura, M., Vita F.D., and Ciardiello, F. (2009). Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 158, 1-9.
62. Masui, H., Kawamoto, T., Sato, J.D., Wolf, B., Sato, G., and Mendelsohn, J. (1984). Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44, 1002-1007.
63. Mishima, K., Johns, T.G., Luwor, R.B., Scott, A.M., Stockert, E., Jungbluth, A.A., Ji, X.D., Suvarna, P., Voland, J.R., Old, L.J., Huang, H.J.S., and Cavenee, W.K. (2001). Growth suppression of intracranial xenograftedglioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61, 5349-5354.
64. Mohammadnejad, J., Rasaee, M.J., Saqhafi, B., Rajabibazl, M., Rahbarizadeh, F., Omidfar, K., and Paknejad, M. (2006). A new competitive enzyme linked immunosorbent assay (MRP83-CA15-3) for MUC1 measurement in breast cancer. J Immunoassay Immunochem 27, 139-149.
65. Morrison, S.L., Johnson, M.J., Herzenberg, L.A., and Oi, V.T. (1984). Chimeric human-antibody molecules-mouse antigenbinding domains with human constant region domains. Proc Natl Acad Sci 81, 6851-6855.
66. Moscatello, D.K., Holgado-Madruga, M., Godwin, A.K., and Ramirez, G. (1995). Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55, 5536-5539.
67. Muyldermans, S. (2001). Single domain camel antibodies: current status. Rev Mol Biotechnol 74, 277-302.
68. Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J.A., and Hamers, R. (1994). Sequence and structure of VH domain from naturally occurring camel heavy immunoglobulins lacking light chains. Protein Eng 7, 1129-1131.
69. Nakamura, J.L. (2007). The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications. Exp Opin Ter Targets 11, 463-472.
70. Nguyen, V.K., Desmyter, A., and Muyldermans, S. (2001). Functional heavy chain antibodies in Camelidae. Adv Immunol 79, 261-296.
71. Normanno, N., Bianco, C., De Luca, A., Maiello, M.R., and Salomon, D.S. (2003). Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10, 1-21.
72. Okamoto, I., Kenyon, L.C., Emlet, D.R., Mori, T., Sasaki, J., Hirosako, S., Ichikawa, Y., Kishi, H., Godwin, A.K., Yoshioka, M., Suga, M., Matsumoto, M., and Wong, A.J. (2003). Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 94, 50-56.
73. Olapade-Olaopa, E.O., Moscatello, D.K., and Mackay, E.H. (2000). Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82, 186-94.
74. Oldham, R K., and Dillman, R.O. (2008). Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 26, 1774-1777.
75. Omidfar, K., Dehdast, A., Zarei, H., Khorsand, B., and Larijani, B. (2011a). Development of urinary albumin immunosensor based on colloidal AuNP and PVA. Biosens Bioelectron 26, 4177-4183.
76. Omidfar, K., Kashanian, S., Paknejad, M., Kashanian, S., Larijani, B., and Roshanfekr, H. (2007a). Production and characterization of monoclonal antibody against human serum albumin, Hybridoma 26, 215-219.
77. Omidfar, K., Khorsand, B., and Larijani, B. (2011b). Development of a new sensitive immunostrip assay based on mesoporous silica and colloidal Au nanoparticles. Mol Biol Rep 39, 1253-1259.
78. Omidfar, K., Kia, S., Kashanian, S., Paknejad, M., Besharatie, A., Kashanian, S., and Larijani, B. (2010). Colloidal nanogoldbased immunochromatographicstrip test for the detection of digoxin toxicity. Appl Biochem Biotechnol 160, 843-855.
79. Omidfar, K., Kia, S., and Larijani, B. (2011c). Development of a colloidal gold-based immunochromatographictest strip for screening of microalbuminuria. Hybridoma 30, 117-124.
80. Omidfar, K., Moinfar, Z., NaderiSohi, A., Tavangar, S.M., Haghpanah, V, Heshmat, R., Larijani, B. (2009). Expression of EGFRvIII in thyroid carcinoma: immunohistochemicalstudy by camel antibodies. Immunol Invest 38, 165-180.
81. Omidfar, K., Rasaee, M.J., Kashanian, S., Paknejad, M., and Bathaie, Z. (2007b). Studies of thermostability in camelusbactrianus (Bactrian camel) single-domain antibody specific for the mutant epidermal-growth-factor receptor expressed by Pichia. Biotechnol Appl Biochem 46, 41-49.
82. Omidfar, K., Rasaee, M.J., Modjtahedi, H., Forouzandeh, M., Taghikhani, M., Bakhtiari, A., Paknejad, M., and Kashanian, S. (2004a). Production and chacterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus. Tumour Biol 25, 179-187.
83. Omidfar, K., Rasaee, M.J., Modjtahedi, H., Forouzandeh, M., Taghikhani, M., Golmakani, N. (2004b). Production of a novel camel single domain antibody specific for the type III mutant EGFR. Tumour Biol 25, 296-305.
84. Paknejad, M., Rasaee, M.J., Tehrani, F.K., Kashanian, S., Mohagheghi, M.A., Omidfar, K., and Bazl, M.R. (2003). Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin. Hybrid Hybridomics 22, 153-158.
85. Pandey, S. (2010). Hybridoma technology for production of monoclonal antibodies. Int J Pharma Sci Rev Res 1, 88-94.
86. Pandey, M., and Chandramohan, K. (2003). Epidermal growth factor receptor: a novel target for anticancer treatment. World J Surg Oncol 1, 9.
87. Panousis, C., Rayzman, V.M., Johns, T.G., Renner, C., Liu, Z., Cartwright, G., Lee, FT, Wang, D., Gan, H., Cao, D., Kypridis, A., Smyth, F.E., Brechbiel, M.W., Burgess, A.W., Old, L.J., and Scott, A.M. (2005). Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer 92, 1069-1077.
88. Pedersen, M.W., Meltorn, M., Damstrup, L., and Poulsen, H.S. (2001). The type III epidermal growth factor receptor mutation: biological significance and potential target for anticancer therapy. Ann Oncol 12, 745-760.
89. Reist, C.J., Archer, G.E., Kurpad, S.N., Wikstrand, C.J., Vaidyanathan, G., Willingham, M.C., Moscatello, D.K., Wong, A.J., Bigner, D.D., and Zalutsky, M.R. (1995). Tumor-specific antiepidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobioseradioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55, 4375-4382.
90. Revets, H., De Baetselier, P., and Muyldermans, S. (2005). Nanobodies as novel agents for cancer therapy. Expert Opin Invest Drugs 5, 111-124.
91. Rodŕguez, M.O., Rivero, T.C., Bahi, R.C., Muchuli, C.R., Bilbao, M.A., VinagerasE N., Alert, J., Galainena, J.J., Rodŕguez, E., Gracias, E., Mulén, B., Wilkinson, B., Armas, E.L., Pérez, K., Pineda, I., Frómeta, M., Leonard, I., Mullens, V., Viada, C., Luaces, P., Torres, O., Iznaga, N., and Crombe, T. (2010). Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 9, 343-349.
92. Roovers, R.C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A.J., Revets, H., de Haard, H.J., and van Bergen en Henegouwen, P.M. (2007a). Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother 56, 303-317.
93. Roovers, R.C., Van Dongen, G.A., and Henegouwen, P.M.B. (2007b). Nanobodies in therapeutic applications. Curr Opin Mol Ther 9, 327-335.
94. Roovers, R.C., Vosjan, M.J.W.D., Laeremans, T., Khoulati, R., Khoulati, R., de Bruin, R.C., Ferguson, K M., Verkleij, A.J., Dongen, G.A.M.S., and van Bergen en Henegouwen, P.M. (2011). A bi-paratopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer 129, 2013-2024.
95. Salomon, D.S., Brandt, R., Ciardiello, F., and Normanno, N. (1995) Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19, 183-232.
96. Sampsona, J.H., Archera, G.E., Mitchell, D.A., Heimberger, A.B., and Bigner, D.D. (2008). Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20, 267-275.
97. Schmidt, M., Maurer-Gebhard, M., Groner, B., Kohler, G., Brochmann-Santos, G., and Wels, W. (1999). Suppression of metastasis formation by a recombinant single chain antibodytoxin targeted to full length and oncogenic variant EGF receptors. Oncogene 18, 1711-1721.
98. Schrama, D., Reisfeld, R.A., and Becker, J.C. (2006). Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5, 147-159.
99. Schroff, R.W., Foon, K.A., Beatty, S.M., Oldham, R.K., and Morgan, J.A.C. (1985). Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45, 879-885.
100. Scott, A.M., Fook-Thean, L.,Niall, T., Herbertson, R., Gill, S.S.., Liu, Z., Skrinos, E., Murone, C., Saunder, T.H., Chappe, B., Papenfuss, A.T., Poon, A.M.T., Hopkins, W., Smyth, F.E., Mac- Gregor, D., Cher, L.M., Jungbluth, A.A., Ritter, G., Brechbiel, M.W., Murphy, R., Burgess, A.W., Hoffman, E W., Johns, T.G., and Old, L.J. (2007). A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci 104, 4071-4076.
101. Sehrawat, S., and SinghVeterinary, A. (2006). Anti-erythrocyte natural antibody activity in the unconventional 'heavy chain' immunoglobulins of Indian desert camel (Camelusdromedarius). Immunol Immunopathol 111, 139-147.
102. Shankar, S., Vaidyanathan, G., Kuan, C.T., Bigner, D.D., and Zalutsky, M.R. (2006). Anti epidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nucl Med Biol 33, 101-110.
103. Shawler, D.L., Bartholomew, R.M., Smith, L.M., and Dillman, R.O. (1985). Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135, 1530-1535.
104. Smith, J., Kontermann, R.E., Embleton, J., and Kumar, S. (2005). Antibody phage display technologies with special reference to angiogenesis. FASEB J 19, 331-341.
105. Sok, J.C., Coppelli, F.M., Thomas, S.M., Lango, M.N., Xi, S., Hunt, J.L., Freilino, M.L., Graner, M.W., Wikstrand, C.J., Bigner, D.D., Gooding, W.E., Furnari, F.B., Grandis, J.R. (2006). Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12, 5064-5073.
106. Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H., Wyns, L., Senter, P., Revets, H., De Baetselier, P., Muyldermans, S., and Magez, S. (2004). Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 279, 1256-1261.
107. Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H., Wyns, L., Senter, P., and Tillib, S.V. (2011). Camel nanoantibody is an efficient tool for research, diagnostics and therapy. Mol Biol 45, 77-85.
108. To, R., Hirama, T., Arbabi-Ghahroudi, M., MacKenzie, R., Wang, P., Xu, P., Ni, F., and Tanha, J. (2005). Isolation of monomeric human V(H)s by a phage selection. J Biol Chem 280, 41395-41403.
109. Trejtnar, F., and Laznicek, M. (2002). Analysis of renal handling of radiopharmaceuticals. Q J Nucl Med 46, 181-194.
110. Uberall, I., Kolar, Z., Trojanec, R., Berkovcova, J., and Hajduch, M. (2008). The status and role of ErbB receptors in human cancer. Exp Mol Pathol 84, 79-89.
111. van der Linden, R., de Geus, B., Stock, W., Bos,W., vanWassenaar, D., Verrips, T., and Frenken, L. (2000). Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Llama glama. J Immunol Methods 240, 185-195.
112. van der Linden, R.H., Frenken, L.G., de Geus, B., Harmsen, M.M., Ruuls, R.C., Stok, W., de Ron, L., Wilson, S., Davis, P., and Verrips, C.T. (1999). Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1431, 37-46.
113. Verhoeyen, M., Milstein, C., and Winter, G. (1988). Reshaping human antibodies: grafting an antilysozyme activity. Science 239, 1534-1536.
114. Vosjan, M.J.W.D., Perk, L.R., Roovers, R.C., Visser, G.W., Walsum, S.M., and Henegouwen, D.G.A. (2011). Facile labelling of an anti-epidermal growth factor receptor nanobody with 68Ga via a novel bifunctionaldesferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging 38, 753-763.
115. Wikstrand, C.J., Hale, L.P., Batra, S.K., Hill, M.L., Humphrey, P.A., Kurpad, S.N., McLendon, R.E., Moscatello, D., Pegram, C.N., Reist, C.J., Traweek, T., Wong, A.J., Zalutsky, M.R., and Bigner, D.D. (1995). Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55, 3140-3148.
116. Wikstrand, C.J., McLendon, R.E., Friedman, A.H., and Bigner, D.D. (1997). Cell surface localization and density of the tumorassociated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57, 4130-4140.
117. Wu, A.M., Tan, G.J., Sherman, M.A., Clarke, P., Olafsen, T., Forman, S.J., and Raubitschek, A.A. (2001). Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng 14, 1025-1033.
118. Wykosky, J., Fenton, T., Furnari, F., and Cavenee, W.K. (2011). Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer 30, 5-12.
119. Yaish, P., Gazit, A., Gilon, C., and Levitzki, A. (1988). Blocking of EGF dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933-935.
120. Yang, W., Barth, R.F., Wu, G., Sferra, T.J., Bandyopadhyaya, A.K., Tjarks, W., Ferketich, A.K., Moeschberger, M.L., Binns, P.J., Riley, K.J., Coderre, J.A., Ciesielski, M.J., Fenstermaker, R.A., and Wikstrand, C.J. (2006). Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res 12, 3792-3802.
121. Yarden, Y. (2001). The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37, 3-8.